Stress Ulcer Prophylaxis with a Proton Pump Inhibitor Versus Placebo in Critically Ill Patients (SUP-ICU Trial): Study Protocol for a Randomised Controlled Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2016 Apr 21

PMID 27093939

Citations 17

Authors

Mette Krag

Anders Perner

Jorn Wetterslev

Matt P Wise

Mark Borthwick

Stepani Bendel

Paolo Pelosi

Frederik Keus

Anne Berit Guttormsen

Joerg C Schefold

Morten Hylander Moller

Affiliations

Soon will be listed here.

Abstract

Background: Critically ill patients in the intensive care unit (ICU) are at risk of clinically important gastrointestinal bleeding, and acid suppressants are frequently used prophylactically. However, stress ulcer prophylaxis may increase the risk of serious adverse events and, additionally, the quantity and quality of evidence supporting the use of stress ulcer prophylaxis is low. The aim of the SUP-ICU trial is to assess the benefits and harms of stress ulcer prophylaxis with a proton pump inhibitor in adult patients in the ICU. We hypothesise that stress ulcer prophylaxis reduces the rate of gastrointestinal bleeding, but increases rates of nosocomial infections and myocardial ischaemia. The overall effect on mortality is unpredictable.

Methods/design: The SUP-ICU trial is an investigator-initiated, pragmatic, international, multicentre, randomised, blinded, parallel-group trial of stress ulcer prophylaxis with a proton pump inhibitor versus placebo (saline) in 3350 acutely ill ICU patients at risk of gastrointestinal bleeding. The primary outcome measure is 90-day mortality. Secondary outcomes include the proportion of patients with clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile infection or myocardial ischaemia, days alive without life support in the 90-day period, serious adverse reactions, 1-year mortality, and health economic analyses. The sample size will enable us to detect a 20 % relative risk difference (5 % absolute risk difference) in 90-day mortality assuming a 25 % event rate with a risk of type I error of 5 % and power of 90 %. The trial will be externally monitored according to Good Clinical Practice standards. Interim analyses will be performed after 1650 and 2500 patients.

Conclusion: The SUP-ICU trial will provide high-quality data on the benefits and harms of stress ulcer prophylaxis with a proton pump inhibitor in critically ill adult patients admitted in the ICU.

Trial Registration: ClinicalTrials.gov Identifier: NCT02467621 .

Citing Articles

Complications and Pharmacologic Interventions of Invasive Positive Pressure Ventilation During Critical Illness.

Newsome A, Chastain D, Watkins P, Hawkins W J Pharm Technol. 2021; 34(4):153-170.

PMID: 34860978 PMC: 6041871. DOI: 10.1177/8755122518766594.

Efficient treatment of esophageal nutrition bezoars: dissolution outmatches removal-the Zurich approach.

Morell B, Buehler P, Bader P, Lang S, Scharl M, Gubler C Clin J Gastroenterol. 2021; 14(6):1602-1606.

PMID: 34499314 PMC: 8557172. DOI: 10.1007/s12328-021-01516-1.

Audit on Practices of Stress Ulcer Prophylaxis in Intensive Care Unit Patients.

Gupta D, Bhalotra A, Singh R Indian J Crit Care Med. 2020; 24(3):160-167.

PMID: 32435093 PMC: 7225769. DOI: 10.5005/jp-journals-10071-23368.

Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial.

Granholm A, Marker S, Krag M, Zampieri F, Thorsen-Meyer H, Kaas-Hansen B Intensive Care Med. 2020; 46(4):717-726.

PMID: 31938829 DOI: 10.1007/s00134-019-05903-8.

Pantoprazole prophylaxis in ICU patients with high severity of disease: a post hoc analysis of the placebo-controlled SUP-ICU trial.

Marker S, Perner A, Wetterslev J, Krag M, Lange T, Wise M Intensive Care Med. 2019; 45(5):609-618.

PMID: 30863936 DOI: 10.1007/s00134-019-05589-y.

References

Charlot M, Ahlehoff O, Norgaard M, Jorgensen C, Sorensen R, Abildstrom S . Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010; 153(6):378-86. DOI: 10.7326/0003-4819-153-6-201009210-00005. View

Marik P, Vasu T, Hirani A, Pachinburavan M . Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med. 2010; 38(11):2222-8. DOI: 10.1097/CCM.0b013e3181f17adf. View

Horan T, Andrus M, Dudeck M . CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008; 36(5):309-32. DOI: 10.1016/j.ajic.2008.03.002. View

Wetterslev J, Thorlund K, Brok J, Gluud C . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2007; 61(1):64-75. DOI: 10.1016/j.jclinepi.2007.03.013. View

Leonard J, Marshall J, Moayyedi P . Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007; 102(9):2047-56. DOI: 10.1111/j.1572-0241.2007.01275.x. View

Brett S . Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. Crit Care. 2005; 9(1):45-50. PMC: 1065099. DOI: 10.1186/cc2980. View

. International conference on harmonisation; guidance on statistical principles for clinical trials; availability--FDA. Notice. Fed Regist. 1998; 63(179):49583-98. View

Burgess P, Larson G, Davidson P, Brown J, Metz C . Effect of ranitidine on intragastric pH and stress-related upper gastrointestinal bleeding in patients with severe head injury. Dig Dis Sci. 1995; 40(3):645-50. DOI: 10.1007/BF02064385. View

Eddleston J, Pearson R, Holland J, Tooth J, Vohra A, Doran B . Prospective endoscopic study of stress erosions and ulcers in critically ill adult patients treated with either sucralfate or placebo. Crit Care Med. 1994; 22(12):1949-54. View

10.

Martin L . Stress ulcers are common after aortic surgery. Endoscopic evaluation of prophylactic therapy. Am Surg. 1994; 60(3):169-74. View

11.

Apte N, Karnad D, Medhekar T, Tilve G, Morye S, Bhave G . Gastric colonization and pneumonia in intubated critically ill patients receiving stress ulcer prophylaxis: a randomized, controlled trial. Crit Care Med. 1992; 20(5):590-3. DOI: 10.1097/00003246-199205000-00008. View

12.

FRIEDMAN C, Oblinger M, Suratt P, Bowers J, Goldberg S, Sperling M . Prophylaxis of upper gastrointestinal hemorrhage in patients requiring mechanical ventilation. Crit Care Med. 1982; 10(5):316-9. View

13.

Zinner M, Zuidema G, Smith PL , Mignosa M . The prevention of upper gastrointestinal tract bleeding in patients in an intensive care unit. Surg Gynecol Obstet. 1981; 153(2):214-20. View

14.

Basso N, Bagarani M, Materia A, Fiorani S, Lunardi P, Speranza V . Cimetidine and antacid prophylaxis of acute upper gastrointestinal bleeding in high risk patients. Controlled, randomized trial. Am J Surg. 1981; 141(3):339-41. DOI: 10.1016/0002-9610(81)90191-4. View

15.

Halloran L, Zfass A, Gayle W, WHEELER C, Miller J . Prevention of acute gastrointestinal complications after severe head injury: a controlled trial of cimetidine prophylaxis. Am J Surg. 1980; 139(1):44-8. DOI: 10.1016/0002-9610(80)90228-7. View

16.

MacDougall B, Bailey R, Williams R . H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trials. Lancet. 1977; 1(8012):617-9. DOI: 10.1016/s0140-6736(77)92055-4. View

17.

Schafer J, Graham J . Missing data: our view of the state of the art. Psychol Methods. 2002; 7(2):147-77. View

18.

Fennerty M . Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med. 2002; 30(6 Suppl):S351-5. DOI: 10.1097/00003246-200206001-00002. View

19.

Cook D, Griffith L, Walter S, Guyatt G, Meade M, Heyland D . The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 2001; 5(6):368-75. PMC: 83859. DOI: 10.1186/cc1071. View

20.

Altman D, Schulz K, Moher D, Egger M, Davidoff F, Elbourne D . The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001; 134(8):663-94. DOI: 10.7326/0003-4819-134-8-200104170-00012. View